in Tag: Safety (clear all)
Showing 1 to 7
Safety of Veterinary Biologicals (MCC: 3.08, Jan 2004)
This guideline provides information on the safety aspects of veterinary biological medicines. Circular 3.0 H
Related Tags (New Search): Biological medicines, Safety and performance, Safety, Veterinary medicine
SAFETY-RELATED PACKAGE INSERT NOTIFICATIONS (SR-PINs) - (MCC: Aug 17)
Safety-related Package Insert Notifications (SR PINS) in South Africa.Circular 2.17.
Related Tags (New Search): Allopathic medicines, Complementary medicines, Safety, Adverse Drug Reaction, SRPINS, Adverse Drug Event, Post-marketing
Post-Marketing Reporting of Adverse Drug Reactions to Human Medicinal Products in South Africa (MCC: 2.33, Sept 2016)
The document assist the reporting of adverse drug reactions (ADRs) and in the management of safety data during post-registration and post-marketing clinical trials. To confirm that you have the latest version of this document, please visit: http://www.mccza.com
Related Tags (New Search): Safety, Adverse Drug Reaction, Clinical trials, Medicines
Guidelines for Recall/Withdrawal of Medicines, Medical Devices and IVDs (MCC: 5.07, Nov 2015)
This is a draft guideline incorporating medical devices. Not yet finalised
Related Tags (New Search): GMP, QMS, IVDs, Non-compliance, Recall, Recalls, Safety, Adverse Drug Reaction, SRPINS, Adverse Drug Event
Good Clinical Practices: Emergency Trolley (MCC: 9.60, Jun 2015)
Requirement for all site conducting clinical trials to have an emergency trolley. Please note that this is a third-party website. Juta has no control over the nature, content or availability of third-party websites, and shall not be liable, in any manner…
Related Tags (New Search): Safety, Emergency, Clinical trials
POST-MARKETING REPORTING OF ADVERSE DRUG REACTIONS TO HUMAN MEDICINES IN SOUTH AFRICA (MCC: June 2017)
Post-Marketing Reporting of Adverse Drug Reactions to Human Medicines in South Africa
Related Tags (New Search): Allopathic medicines, Complementary medicines, Safety, Adverse Drug Reaction, SRPINS, Adverse Drug Event, Post-marketing